Crestchem Limited - healthcare in Indrad, Gujarat, India. FY 2026 financials & compliance.
CIN L24100GJ1991PLC015530 Incorporated 26 April 1991 ROC Ahmedabad HQ Indrad, Gujarat, India
Active Listed - BSE: 526269 Public Limited Company healthcare MSME · Small
Data last updated
Market Cap
₹46.47 Cr
CRSTCHM · BSE
Share Price
₹142.10
-8.26% today
Revenue
₹29.61 Cr
FY 2025-26
EBITDA
₹3.19 Cr
Margin 10.8%
Net Profit
₹2.72 Cr
FY 2025-26
P/E (TTM)
17.0x
P/B 4.7x
ROE
27.4%
ROCE 37.8%
Authorised capital
₹4 Cr
Registered with MCA

About Crestchem Limited

Data last updated:

Crestchem Limited is a public limited company based in Indrad, Gujarat, India. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 26 April 1991 and has been in existence for over 35 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24100GJ1991PLC015530. Its GSTIN is 24AAACC8722C1Z5 (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 526269.

The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹3 Cr. It is led by directors including Dipak Narendraprasad Patel (Managing Director) and Rinkal Maulik Jasani.

Its last annual general meeting (AGM) was held on 21 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sr. No.550/1 Sub Plot No. 12 Village – Indrad Taluka – Kadi, Gujarat, India – 382715.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹29.61 Cr. For the same year it recorded a net profit of ₹2.72 Cr (net margin 9.2%) and EBITDA of ₹3.19 Cr (EBITDA margin 10.8%). The net worth stands at ₹9.89 Cr. Total assets are valued at ₹9.96 Cr.

The company is associated with 1 brand: Crestchem. Court records list 6 cases involving the company, including 1 filed by the company and 5 filed against it; 1 case is pending. The company has 2 deals on record (2 market trades); the latest was in September 2023. Its 5 peer companies in the Healthcare industry (Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 3 smaller; the largest is Biovencer Healthcare Private Limited with revenue of ₹28.51 Cr.

Crestchem Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0001783). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website crestchemlimited.in.

Company details

CIN L24100GJ1991PLC015530
Registration Number 015530
Incorporation Date 26 April 1991
ROC Ahmedabad
Listing Status Listed - Listed on BSE (526269)
Company Status Active
Date of Last AGM 21 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-01-0001783

CIN history

Crestchem has one previous CIN (Corporate Identification Number): L24100GJ1991PTC015530. The current CIN is L24100GJ1991PLC015530, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24100GJ1991PLC015530Current
L24100GJ1991PTC015530Previous

Recognitions & Rankings of Crestchem

MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-GJ-01-0001783

Contact details

Crestchem Limited's registered office is in Indrad, Gujarat. Its website is crestchemlimited.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Sr. No.550/1 Sub Plot No. 12 Village – Indrad Taluka – Kadi, Gujarat, India – 382715
  • Industry
    Healthcare, Preventive Health Supplements

To see the full contact details of Crestchem Limited, buy the company report.

Comprehensive company report
Crestchem Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Crestchem operates one associated brand: Crestchem. Each brand links to its own profile.

BrandDescriptionWebsite
Triglycerides and skimmed milk powder are manufactured by Crestchem.crestchemlimited.in

Business activity

The main business activity of Crestchem is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Crestchem Limited, buy the company report.

Financials of Crestchem Limited

FY 2025-26 filings available

Crestchem Limited reported revenue of ₹29.61 Cr for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹29.61 Cr
EBITDA
₹3.19 Cr
Profit After Tax
₹2.72 Cr
Net Worth
₹9.89 Cr
Total Assets
₹9.96 Cr
Total Debt
Nil

Financial summary ₹ Cr

MetricsFY 2025-26
Income statement
Revenue29.61
EBITDA3.19
EBITDA margin+10.8%
Profit before tax3.77
Net profit2.72
Net profit margin+9.2%
EPS (₹)9.05
Balance sheet
Total assets9.96
Net worth9.89
Total debt0.00
Cash & bank0.41
Net working capital(0.62)
Cash flow
Cash from operations3.59
Cash from investing(3.75)
Cash from financing(0.17)
ParticularsJun 2026Mar 2026
Revenue9.2610.23
Other income0.200.20
EBITDA1.141.40
EBITDA margin+12.3%+13.7%
Depreciation0.010.02
Interest0.010.01
Profit before tax1.321.57
Tax0.380.48
Net profit0.941.09
EPS (₹)3.143.67
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue29.6125.0821.2616.737.957.646.20
Revenue growth+18.1%+18.0%+27.1%+110.4%+4.1%+23.2%-
EBITDA3.193.332.780.830.760.650.56
EBITDA margin+10.8%+13.3%+13.1%+5.0%+9.6%+8.5%+9.0%
Profit before tax3.773.672.980.950.790.660.57
Net profit2.722.742.150.700.580.560.44
Net profit margin+9.2%+10.9%+10.1%+4.2%+7.3%+7.3%+7.1%
EPS (₹)9.059.097.152.311.891.911.48
Balance sheet
Total assets9.947.554.932.772.332.160.93
Net worth9.897.484.902.752.061.490.92
Total debt0.000.000.000.000.270.630.02
Cash & bank0.410.730.150.870.010.970.64
Net working capital(0.72)1.310.09(0.80)0.221.870.72
Cash flow
Cash from operations3.591.660.352.210.820.390.33
Cash from investing(3.75)(0.99)(1.07)(1.34)(0.83)(0.39)(0.35)
Cash from financing(0.17)(0.09)(0.01)(0.01)(0.02)(0.02)0.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.1810.237.167.195.037.234.807.80
Revenue growth (YoY)+82.5%+41.5%+49.2%-7.8%-4.2%---
Other income0.200.200.180.150.130.140.090.12
Total expenses8.008.836.356.584.676.634.156.53
EBITDA1.181.400.810.610.360.600.651.27
EBITDA margin+12.9%+13.7%+11.3%+8.5%+7.2%+8.3%+13.5%+16.3%
Depreciation0.010.020.020.020.020.020.010.01
Interest0.010.010.000.000.000.000.000.00
Profit before tax1.361.570.970.740.470.720.731.38
Tax0.380.480.250.190.120.110.200.39

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsJun 2026Mar 2026
Revenue9.2610.23
Other income0.200.20
EBITDA1.141.40
EBITDA margin+12.3%+13.7%
Depreciation0.010.02
Interest0.010.01
Profit before tax1.321.57
Tax0.380.48
Net profit0.941.09
EPS (₹)3.143.67
ParticularsFY 2025-26
Revenue29.61
Other income0.66
Total expenses26.42
Employee cost1.19
EBITDA3.19
EBITDA margin+10.8%
Depreciation0.07
Interest0.01
Profit before tax3.77
Tax1.05
Net profit2.72
Net profit margin+9.2%
EPS (₹)9.05
ParticularsFY 2025-26
Equity & liabilities
Share capital3.00
Reserves & surplus6.89
Shareholders' funds (net worth)9.89
Minority interest0.03
Secured loans0.00
Unsecured loans0.00
Total debt0.00
Total liabilities9.96
Assets
Gross block1.05
Net block0.20
Capital work in progress0.00
Investments0.00
Inventories0.00
Sundry debtors3.61
Cash & bank balances0.41
Loans & advances1.64
Total current assets5.66
Total current liabilities6.28
Net working capital(0.62)
Total assets9.96
ParticularsFY 2025-26
Opening cash0.73
Net cash from operating activities3.59
Net cash from investing activities(3.75)
Net cash from financing activities(0.17)
Net change in cash(0.33)
Closing cash0.41
ParticularsFY 2025-26
Growth
PBT growth+9997.0%
Profitability & leverage
Net income margin+9.2%
Return on capital employed+37.8%
Return on net worth+27.4%
Debt / equity0.00
Long-term debt / equity0.00
Interest cover0.32
Efficiency & per share
Fixed asset turnover28.20
Inventory turnover0.00
Debtors turnover8.20
EPS (₹)9.05
Dividend per share (₹)1.50
Book value per share (₹)32.95
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.1810.237.167.195.037.234.807.80
Revenue growth (YoY)+82.5%+41.5%+49.2%-7.8%-4.2%---
Other income0.200.200.180.150.130.140.090.12
Total expenses8.008.836.356.584.676.634.156.53
EBITDA1.181.400.810.610.360.600.651.27
EBITDA margin+12.9%+13.7%+11.3%+8.5%+7.2%+8.3%+13.5%+16.3%
Depreciation0.010.020.020.020.020.020.010.01
Interest0.010.010.000.000.000.000.000.00
Profit before tax1.361.570.970.740.470.720.731.38
Tax0.380.480.250.190.120.110.200.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue29.6125.0821.2616.737.957.646.20
Revenue growth+18.1%+18.0%+27.1%+110.4%+4.1%+23.2%-
Other income0.660.440.260.150.080.050.03
Total expenses26.4221.7518.4815.907.196.995.64
Employee cost1.191.160.670.530.260.470.13
EBITDA3.193.332.780.830.760.650.56
EBITDA margin+10.8%+13.3%+13.1%+5.0%+9.6%+8.5%+9.0%
Depreciation0.070.050.050.020.030.020.02
Interest0.010.050.010.010.020.020.00
Profit before tax3.773.672.980.950.790.660.57
Tax1.050.930.830.250.210.100.13
Net profit2.722.742.150.700.580.560.44
Net profit margin+9.2%+10.9%+10.1%+4.2%+7.3%+7.3%+7.1%
EPS (₹)9.059.097.152.311.891.911.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.003.003.003.003.003.003.00
Reserves & surplus6.894.481.90(0.25)(0.94)(1.51)(2.08)
Shareholders' funds (net worth)9.897.484.902.752.061.490.92
Secured loans0.000.000.000.000.270.630.02
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.000.000.000.000.270.630.02
Total liabilities9.947.554.932.772.332.160.93
Assets
Gross block1.051.050.910.790.770.770.72
Net block0.200.270.180.100.110.130.11
Capital work in progress0.000.000.000.000.000.000.00
Investments0.080.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.01
Sundry debtors3.612.561.530.020.901.411.21
Cash & bank balances0.410.730.150.870.010.970.64
Loans & advances1.611.020.620.330.270.310.21
Total current assets5.634.312.301.221.182.692.07
Total current liabilities6.353.002.212.020.960.821.35
Net working capital(0.72)1.310.09(0.80)0.221.870.72
Total assets9.947.554.932.772.332.160.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.730.150.870.010.030.050.07
Net cash from operating activities3.591.660.352.210.820.390.33
Net cash from investing activities(3.75)(0.99)(1.07)(1.34)(0.83)(0.39)(0.35)
Net cash from financing activities(0.17)(0.09)(0.01)(0.01)(0.02)(0.02)0.00
Net change in cash(0.33)0.59(0.72)0.86(0.02)(0.01)(0.02)
Closing cash0.410.730.150.870.010.970.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.1%+18.0%+27.1%+110.4%+4.1%+23.2%-
EBITDA growth-4.2%+19.8%+234.9%+9.2%+16.9%+16.1%-
PBT growth+2.7%+23.2%+213.7%+20.3%+19.7%+15.8%+9998.0%
Net income growth-0.7%+27.4%+207.1%+20.7%+3.6%+27.3%-
Revenue CAGR (3Y)+21.0%+46.7%+40.7%+39.2%+330.0%+434.6%+253.8%
EBITDA CAGR (3Y)+56.6%+63.6%+62.3%+14.0%---
Profitability & leverage
Net income margin+9.2%+10.9%+10.1%+4.2%+7.3%+7.3%+7.1%
Return on capital employed+43.0%+59.4%+75.2%+29.9%+23.1%+20.6%+30.2%
Return on net worth+31.2%+44.1%+54.4%+23.0%+19.0%+19.0%+25.4%
Debt / equity0.000.000.000.050.250.270.22
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.321.520.371.232.743.170.00
Efficiency & per share
Fixed asset turnover28.2025.5925.0121.4510.3210.268.67
Inventory turnover0.000.000.000.000.001,528.00620.00
Debtors turnover9.6012.2627.4336.376.885.839.61
EPS (₹)9.059.097.152.311.891.911.48
Dividend per share (₹)1.501.000.500.000.000.000.00
Book value per share (₹)32.9524.9216.339.186.874.973.06

To see the full year-wise statements and ratios of Crestchem Limited, buy the company report.

Board of directors of Crestchem Limited

Crestchem has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Dipak Narendraprasad PatelManaging Director01 Feb 200818 Years 8 MonthsCurrent
Rinkal Maulik JasaniDirector28 May 20251 Years 5 MonthsCurrent
Priyankaben Manojkumar PatelDirector04 Jul 20242 Years 3 MonthsCurrent
Jignesh Ashvinkumar ShahDirector29 Dec 20232 Years 9 MonthsCurrent
Nirmit Dipak PatelDirector17 Jul 20233 Years 3 MonthsCurrent

Peer comparison

Crestchem Limited is compared with the 5 companies closest to it by revenue in the Healthcare industry (Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Crestchem Limitedthis company₹29.61 Cr (FY 2026)₹2.72 Cr9.2%Indrad, Gujarat, India
Biovencer Healthcare Private Limited₹28.51 Cr (FY 2025)-1.0%Greater Noida, Uttar Pradesh, India
Molclone Labs Private Limited₹25.57 Cr (FY 2025)12.0%Chennai, Tamil Nadu, India
Novel Nutrientss Private Limited₹25.26 Cr (FY 2024)-1.0%Bangalore, Karnataka, India
Healkraft Pharma (India) Private Limited₹25.01 Cr (FY 2025)-1.0%Chennai, Tamil Nadu, India
Zeon Biotech Private Limited₹24.1 Cr (FY 2024)19.0%Ahmedabad, Gujarat, India

To see the full peer comparison of Crestchem Limited, buy the company report.

Auditor

Crestchem Limited is audited by SAMIR M SHAH & ASSOCIATES for the financial year 2023.

Auditor firmFinancial yearFirm registration number
SAMIR M SHAH & ASSOCIATESFY 2023122377W

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 30.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 69.90%.

Promoters: 30.00%DII (Domestic Institutional): 0.10%Retail & Others: 69.90%
Mar 2026
QUARTER
30.00% Promoters
0.10% DII (Domestic Institutional)
69.90% Retail & Others
Promoter holding - history
Now 30.00% · Mar 2026High 30.00% · Mar 2026Low 29.40% · Jun 2025
28%28.8%29.5%30.3%31%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 29.40%Sep 2025: 29.70%Dec 2025: 29.90%Mar 2026: 30.00%29.40%30.00%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters30.00%29.90%29.70%29.40%
Public70.00%70.10%70.30%70.60%

Deals & funding

Crestchem Limited has 2 deals on record (2 market trades); the latest was in September 2023.

Total deals
2
Market trades
2

Deals on record (2 of 2)

WhenDealAmountParties
Sep 2023Market trade₹13.8 LakhSeller: an individual
Nov 2020Market trade₹19.6 LakhBuyer: an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Crestchem Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Crestchem has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24AAACC8722C1Z5GujaratActive01 Jul 2017

To see the full GST registrations and return filing status of Crestchem Limited, buy the company report.

Recent activity

Crestchem Limited has 20 board changes on record since 1991: 13 appointments and 7 cessations. The latest: Nitinkumar Shantilal Shah was appointed as Company Secretary on 25 Aug 2025.

Filing
Crestchem Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Nitinkumar Shantilal Shah was appointed as Company Secretary.
AGM
Crestchem Limited last Annual general meeting of members was held on 21 Aug 2025 as per latest MCA records.
Appointed
Rinkal Maulik Jasani was appointed as Director.
Ceased
Binaben Parasbhai Patel ceased to be Director.
Ceased
Manojkumar Babubhai Patel ceased to be Director.
Appointed
Priyankaben Manojkumar Patel was appointed as Director.
Ceased
Rajesh Ishwarlal Mody ceased to be Director.
Appointed
Jignesh Ashvinkumar Shah was appointed as Director.
Appointed
Nirmit Dipak Patel was appointed as Director.
Appointed
Manojkumar Babubhai Patel was appointed as Director.
Ceased
Neil Darshan Dalal ceased to be Whole-Time Director.

11 earlier events are in the company report.

Frequently asked questions

Crestchem is an active public limited company based in Indrad, Gujarat, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 26 April 1991 (35+ years old) and is registered under CIN L24100GJ1991PLC015530. Listed on BSE: 526269.

Crestchem reported revenue of ₹29.61 Cr for FY 2025-26 based on consolidated financials.

Crestchem has 5 current directors:

The latest financial statements of Crestchem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 21 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Crestchem is 24AAACC8722C1Z5, registered in Gujarat.

The CIN (Corporate Identification Number) of Crestchem is L24100GJ1991PLC015530. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Crestchem is a listed company as per MCA records. Its shares are listed on BSE (code: 526269).

Crestchem has 6 court cases on record: 1 filed by the company and 5 filed against it. 1 is pending. Most are in the district courts.

Crestchem was incorporated on 26 April 1991, making it 35+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Crestchem has 2 deals on record (2 market trades); the latest was in September 2023.

The peers of Crestchem by revenue are Biovencer Healthcare Private Limited, Molclone Labs Private Limited, Novel Nutrientss Private Limited, Healkraft Pharma (India) Private Limited, Zeon Biotech Private Limited, all in the Healthcare industry (Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).